Johnson & Johnson would be just fine without Zytiga, executives insist as patent decision looms
admin 16th October 2018 Uncategorised 0J&J could suffer a big patent loss for its blockbuster cancer treatment Zytiga—and soon—but even if that happens, the company argues it can grow faster than its peers, thanks to its wide pharmaceuticals portfolio.
More: Johnson & Johnson would be just fine without Zytiga, executives insist as patent decision looms
Source: fierce